Merck’s new drug application for an investigational intravenous (IV) formulation of NOXAFIL® (posaconazole) receives FDA priority review
18 November 2013 | By Merck
Marketing authorization application also filed with the European Medicines Agency...
List view / Grid view
News
RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD
18 November 2013 | By GlaxoSmithKline
RELVAR® ELLIPTA® is now licensed across 31 European countries...
3D cell-based models for regenerative medicine and drug discovery
18 November 2013 | By AMSBIO
Presented by Dr Elad Katz, a senior scientist at AMSBIO, a new on-demand webinar explores the potential of 3D cell-based models for regenerative medicine and drug discovery.
Abbott named Top Dealmaker for sixth consecutive year by The Deal
18 November 2013 | By Abbott
Abbott was recognized by The Deal as the best all-around dealmaker in healthcare...
NovoEight® passed the review by the Committee on Drugs of Pharmaceutical Affairs in Japan
18 November 2013 | By Novo Nordisk
NovoEight® has passed the review by the Committee on Drugs of Japan's Pharmaceutical Affairs and Sanitation Council...
Additional interim data for Merck’s investigational anti-PD-1 immunotherapy, MK-3475, shows estimated overall survival rate of 81% at one year in patients with advanced melanoma
18 November 2013 | By Merck
“I am excited by the results seen for MK-3475 to date as a single agent..."
Amgen presents interim overall survival data from Phase 3 study of Talimogene Laherparepvec in patients with metastatic melanoma
18 November 2013 | By Amgen
Differences in survival rates were pronounced in the subset of patients with stage IIIB, IIIC or IV M1a disease...
Boehringer Ingelheim goes “Blue” in supporting World Diabetes Day activities
15 November 2013 | By Boehringer Ingelheim
"Run for Diabetes" raises €15,000 towards supporting "Life for a Child Programme..."
Novartis announces positive clinical trial results for novel H7N9 vaccine
14 November 2013 | By Novartis
85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59® adjuvant...
Bristol-Myers Squibb Foundation marks World Diabetes Day with four grants addressing link between diabetes, depression and distress
14 November 2013 | By Bristol-Myers Squibb
“There is a need for the development of short- and long-term diabetes care models and self-management programs..."
Amgen to highlight new Evolocumab (AMG 145) data at upcoming American Heart Association Scientific Sessions 2013
14 November 2013 | By Amgen
First long-term data of a PCSK9 Inhibitor to be featured in clinical science: special reports session...
Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat® to the treatment of asthma in adults aged 18 years and over
13 November 2013 | By Boehringer Ingelheim
"Our extensive studies have demonstrated that tiotropium Respimat® has the potential to be an effective new treatment..."
Leading hematology journal publishes pivotal ELOCTATE™ data that demonstrated efficacy and safety of investigational long-lasting therapy for hemophilia A
13 November 2013 | By Biogen Idec
Phase 3 study showed potential for once- or twice-weekly prophylactic dosing regimens...
IMBRUVICA™ (ibrutinib) capsules now approved in the U.S. for Mantle Cell Lymphoma patients who have received at least one prior therapy
13 November 2013 | By Johnson & Johnson
Janssen Biotech, Inc. [“Janssen”] today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.1 This indication is based on overall response rate (ORR). An improvement in survival or…
Abbott supports relief efforts in the Philippines
13 November 2013 | By Abbott
The Abbott Fund provide $450,000 in grants and healthcare products to help people affected by super typhoon...
